PDS Biotechnology (PDSB)
(Delayed Data from NSDQ)
$1.13 USD
+0.01 (0.89%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.12 -0.01 (-0.88%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PDSB 1.13 +0.01(0.89%)
Will PDSB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PDSB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PDSB
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
PDSB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
Best Momentum Stocks to Buy for October 15th
Other News for PDSB
12 Health Care Stocks Moving In Wednesday's After-Market Session
PDS Biotechnology (PDSB) Advances in Clinical Trial for Colorectal Cancer | PDSB Stock News
PDS Biotech completes patient recruitment in Stage 1 colorectal cancer trial
PDS Biotechnology (PDSB) Retains "Buy" Rating with Price Target Unchanged | PDSB ...
PDS Biotechnology Updates on HPV16 Cancer Trial Progress